Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations
This case suggests that CGP can help identify actionable alterations in eAML, such as <i>TSC2</i> mutations, to guide personalized therapy with mTOR inhibitors.
Authors
- Hisato Kawakami (ORCID: https://orcid.org/0000-0002-3280-4850)
- Keigo Komine (ORCID: https://orcid.org/0000-0003-2502-3666)
- Masanobu Takahashi
- Yuto Yamazaki (ORCID: https://orcid.org/0000-0002-2373-7756)
- Shiori Ishikawa
- Hidekazu Shirota (ORCID: https://orcid.org/0000-0001-9154-9004)
- Yuki Kasahara
- Hiroo Imai (ORCID: https://orcid.org/0000-0002-1319-724X)
- K Ouchi
- Shonosuke Wakayama
- Ken Saijo
Institutions
- Tohoku University (JP)
- Tohoku University Hospital (JP)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-30
- DOI
- https://doi.org/10.3389/fonc.2026.1735690
- Citations
- 1
- Primary Topic
- Tuberous Sclerosis Complex Research
- Type
- article
- Field-Weighted Citation Impact
- 32.84